Explain It in 30 Seconds
Pfizer bought a selected set of migraine assets rather than absorbing every program associated with the original Biohaven company. Nurtec ODT/Vydura and the CGRP development portfolio became the basis for a larger Pfizer migraine business.
The separation matters to both ownership and attribution. Events at the later independent Biohaven cannot automatically be assigned to Pfizer's acquired franchise, and Pfizer's migraine revenue does not describe all research previously conducted under the Biohaven name.
Deal Timeline
Acquisition announcement
Pfizer proposed buying the CGRP business in a cash transaction described at approximately $11.6 billion. The announced consideration and the scope of the acquired assets answer different questions: one describes the financial commitment, the other describes what the buyer would own. [S20]
October 2022 completion
Completion brought the migraine assets into Pfizer after the non-CGRP programs were separated. This created distinct businesses with different owners and development responsibilities. [S21]
Capability Transfer
A defined treatment franchise
The acquired assets gave Pfizer an established commercial starting point in migraine alongside development opportunities. This differed from acquiring only an early mechanism with no demonstrated demand. It did not remove the need for payer access or continuing product differentiation.
A route through Pfizer's commercial organization
Pfizer could apply its operating resources to the franchise, including regional commercialization and support for market access. Broader reach creates an opportunity when it matches approved uses and available supply; it is not a contractual right to sell the same product in every jurisdiction under identical conditions.
Development beyond the first brand
The acquired portfolio included related CGRP programs. They required their own studies and regulatory outcomes. Existing franchise success could inform investment decisions without establishing the effectiveness or authorization of every subsequent medicine.
The Continuing Commercial Test
Revenue growth depends on more than the number of people with migraine. Diagnosis, prescription decisions, insurance coverage, patient costs and competition all affect the share of demand that becomes recognized revenue. A useful product can face access constraints even when underlying clinical demand exists.
Pfizer also has to earn a return over the franchise's remaining protected life. Additional development or geographic expansion can extend commercial opportunity, but each involves further costs and evidence requirements. The deal's narrow scope helps identify the assets being evaluated; it does not by itself demonstrate that their purchase price was optimal.
What Pfizer Acquired
Nurtec ODT/Vydura, zavegepant (later Zavzpret) and related CGRP programs
Why Pfizer Bought It
Pfizer wanted a scalable migraine franchise that could benefit from its U.S. and international commercial infrastructure.
Post-Acquisition Integration
Nurtec became a $1B+ franchise and Pfizer expanded the portfolio internationally. Non-CGRP development programs remained with a separate New Biohaven.
Strategic Lesson
The deal demonstrates selective M&A: Pfizer bought the strategic franchise rather than the entire target pipeline.
How to Judge the Deal
A pharmaceutical acquisition should be evaluated across several time horizons.
Immediate
- acquired revenue;
- acquired pipeline;
- integration cost;
- financing.
Medium term
- indication expansion;
- commercial execution;
- R&D progression;
- manufacturing scale.
Long term
- new medicines created from the platform;
- durability after acquired patents expire.
The purchase price alone cannot answer whether the deal worked.
Accounting Risk
Large pharmaceutical acquisitions create substantial intangible assets and acquired in-process R&D.
If programs fail or commercial forecasts deteriorate, Pfizer can record non-cash impairment charges.
That means:
strategic acquisition
+
later clinical/commercial setback
↓
GAAP impairmentAn impairment matters, but it is not the same thing as a cash payment occurring again.
Evidence
Why CGRP Was Attractive
Migraine is common, recurrent and significantly disabling.
CGRP therapies created a modern mechanism-based category with both preventive and acute options.
Pfizer saw an opportunity to apply its commercial reach to a product that had already demonstrated meaningful market demand.
Deal Design
The transaction separated the mature strategic CGRP franchise from other early programs.
This separated the acquired franchise from programs that continued in another company; it does not establish a hypothetical price for buying the entire original business.
It is a useful example of acquisition scope discipline.